Large Simple Trial (LST) Of Cardiovascular Safety Of Ziprasidone And Olanzapine- (Zodiac)

Completed · Phase 4

Conditions studied: Schizophrenia

In brief

The primary objective of the study is to estimate the relative incidence among users of ziprasidone and olanzapine of non-suicide mortality.

Key facts

Study ID

NCT00418171

Run by

Pfizer

People needed

18239

Starts

2002-02-01

Expected to finish

2007-04-01

Last updated by the study team

2009-10-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients newly treated for schizophrenia and those receiving continuing treatment will be eligible if the treating psychiatrist is ready to initiate a new antipsychotic medication, and would consider using either ziprasidone or olanzapine as an appropriate therapy.
• Male and female patients who meet all criteria listed below are eligible to be enrolled in this study:
• Diagnosed with schizophrenia
• Willing to provide information on at least one alternate contact person for study staff to contact regarding patient's whereabouts, should the patient be lost-to-follow-up over the course of the study

You may not qualify if…

• Progressive fatal disease of a life expectancy which prohibits them from participating in a one year research study
• Previously randomized to study medication and enrolled in this study

Where it is running

• Pfizer Investigational Site — San Bernardino, California, United States
• Pfizer Investigational Site — ‘Aiea, Hawaii, United States
• Pfizer Investigational Site — Schaumburg, Illinois, United States
• Pfizer Investigational Site — Grants Pass, Oregon, United States
• Pfizer Investigational Site — White Hall, West Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.